If youâre looking for ASX 200 shares to add to your portfolio, then you may want to look at the two named below that have been tipped as buys by analysts at Morgans following the release of their results.
Hereâs why the broker is very positive on these shares:
Cochlear Limited (ASX: COH)
The first ASX 200 share that Morgans is bullish on is Cochlear.
It is a manufacturer and distributor of cochlear implantable devices for the hearing impaired across over 30 countries. It offers three main products: Cochlear implants, Baha bone conduction implants, and Cochlear Wireless Accessories.
Morgans was pleased with Cochlearâs recent half year update. It commented:
Cochlear’s 1H results were better than expected, underpinned by strong sales growth in both developed and emerging markets, but OPM declined on growth initiatives. [â¦] We see continued momentum, with FY23 guidance reaffirmed, implying a strong 2H (+25% at the mid-point), underpinned by strong fundamentals and progressively improving trading conditions.
The broker has an add rating and $250.60 price target on its shares.
Corporate Travel Management Ltd (ASX: CTD)
Another ASX 200 share that Morgans is bullish on right now is corporate travel specialist Corporate Travel Management. It believes it is well-placed for growth over the medium term. This is thanks to acquisitions, its lower cost base, and technology development.
In response to its half year results, Morgans commented:
CTD’s 1H23 result was a slight miss compared to implied guidance and our forecast. However, the result included additional costs so that CTD can take advantage of the expected strong recovery in the 2H23 and FY24. The midpoint of FY23 EBITDA guidance was slightly better than consensus however higher D&A and tax results in NPATA downgrades. CTD is confident of achieving a full recovery in FY24 based on significant new clients wins.
Morgans currently has an add rating and $21.90 price target on the companyâs shares.
The post 2 ASX 200 shares to buy post-results: Morgans appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the ‘five best ASX stocks’ for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now…
See The 5 Stocks
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Here are the top 10 ASX 200 shares today
- 4 ASX 200 shares rerated by brokers following earnings results
- Here are the top 10 ASX 200 shares today
- Why did the ASX 200 leap higher on rising unemployment data?
- Buy these 2 struggling ASX 200 shares now while they’re cheap: fund
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear and Corporate Travel Management. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/4MuDy2t
Stock Pick 